Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications - 09/07/21
, Michael Weber, MD, PhD b, Roland E. Schmieder, MD, PhD c, Melvin D. Lobo, MD, PhD d, Peter J. Blankestijn, MD e, Alexandre Persu, MD, PhD f, Tim A. Fischell, MD g, Helen Parise, ScD h, Atul Pathak, MD, PhD i, David E. Kandzari, MD jRésumé |
Background |
Arterial hypertension is a common and life-threatening condition and poses a large global health burden. Device-based treatments have been developed as adjunctive or alternative therapy, to be used with or without antihypertensive medication for treating uncontrolled hypertension. The safety and feasibility of chemical renal denervation (RDN) using the Peregrine Catheter and alcohol were demonstrated in a first-in-man and open-label clinical trials, prompting the initiation of the ongoing TARGET BP OFF-MED and TARGET BP I trials.
Design |
The TARGET BP trials are randomized, blinded, sham-controlled trials designed to assess the safety and efficacy of alcohol-mediated RDN for the treatment of uncontrolled hypertension in the absence of antihypertensive medications (TARGET BP OFF-MED) or in addition to prescribed antihypertensive medications (TARGET BP I). Subjects with confirmed uncontrolled hypertension and suitable renal artery anatomy are randomized (1:1) to receive either RDN using the Peregrine Kit with alcohol (0.6 mL per renal artery) infused through the Peregrine Catheter or diagnostic renal angiography only (sham procedure). TARGET BP OFF-MED completed enrollment and randomized 96 subjects. TARGET BP I will randomize approximately 300 subjects and will transition to an open-label safety cohort of approximately 300 subjects receiving RDN once the primary efficacy endpoint of the Randomized Controlled Trial (RCT) cohort has been met. Primary endpoints are change in mean 24-hour ambulatory systolic blood pressure from baseline to 8 weeks (TARGET BP OFF-MED) and 3 months (TARGET BP I) post-procedure.
Conclusion |
The TARGET BP trials are the first large-scale, international, randomized trials aimed to investigate the safety and BP lowering efficacy of a novel RDN method, with perivascular alcohol delivery using the Peregrine Kit.
Le texte complet de cet article est disponible en PDF.Plan
Vol 239
P. 90-99 - septembre 2021 Retour au numéro
Article précédent
- Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy
- Milind Y. Desai, Kathy Wolski, Anjali Owens, Srihari S. Naidu, Jeffrey B. Geske, Nicholas G. Smedira, Hartzell Schaff, Kathy Lampl, Ellen McErlean, Christina Sewell, David Zhang, Jay M. Edelberg, Amy J. Sehnert, Steven E. Nissen
- Sacubitril/valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: A randomized, double-blind, active-controlled study
- Marcelo Rodrigues dos Santos, Maria-Janieire de Nazaré Nunes Alves, Camila Paixão Jordão, Caio Eduardo Novaes Pinto, Kelly Thayane Souza Correa, Francis Ribeiro de Souza, Guilherme Wesley Peixoto da Fonseca, Joaquim Tomaz Filho, Marcel Costa, Rosa Maria Rodrigues Pereira, Carlos Eduardo Negrão, Antônio Carlos Pereira Barretto
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?